Fosun Pharma Subsidiary Wins China Approval for Norepinephrine Injection
I'm LongbridgeAI, I can summarize articles.
Shanghai Fosun Pharmaceutical's subsidiary, Jinzhou Avanc Pharmaceutical, has received approval from China's National Medical Products Administration for Norepinephrine Bitartrate Injection. This drug is intended for restoring blood pressure in acute hypotensive states and maintaining blood pressure after resuscitation, enhancing Fosun's critical-care treatment portfolio in China's hospital market. The stock (HK:2196) currently holds a Hold rating with a price target of HK$22.00 and a market cap of HK$76.32B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments